Maitong Biopharmaceutical

Zhejiang Maitong Biopharmaceutical (Meton Pharma) is a Chinese biotechnology company founded in 2020, specializing in the development of first-in-class small molecule drugs targeting metabolic enzymes involved in tumorigenesis. The company's lead candidate, MT-001, is a potent IDH1 inhibitor currently in Phase 1/2 clinical trials for the treatment of IDH1-mutant solid tumors, including glioma, chondrosarcoma, and cholangiocarcinoma. Meton Pharma's pipeline also includes inhibitors targeting IDH2, ME3, IRG1, and PRMT5, as well as antisense oligonucleotides (ASOs) for pancreatic cancer. Led by Academician Zhao Guoping and a team of experienced scientists, the company focuses on leveraging metabolic vulnerabilities in cancer to develop innovative therapies.